These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 6519157)

  • 21. A phase I clinical study of Nimorazole as a hypoxic radiosensitizer.
    Timothy AR; Overgaard J; Overgaard M
    Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1765-8. PubMed ID: 6480460
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase I study of the combined hypoxic cell radiosensitizers, Ro 03-8799 and SR 2508: a preliminary report of single-dose toxicity, pharmacokinetics and tumour concentrations.
    Newman HF; Bleehen NM; Workman P
    Br J Radiol; 1986 Apr; 59(700):423-5. PubMed ID: 2938660
    [No Abstract]   [Full Text] [Related]  

  • 23. Clinical testing of the radiosensitizer Ro 07-0582: experience with multiple doses.
    Dische S; Saunders MI; Lee ME; Adams GE; Flockhart IR
    Br J Cancer; 1977 May; 35(5):567-79. PubMed ID: 861146
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effects of whole body hyperthermia on the pharmacokinetics and toxicity of the basic 2-nitroimidazole radiosensitizer Ro 03-8799 in mice.
    Walton MI; Bleehen NM; Workman P
    Br J Cancer; 1987 May; 55(5):469-76. PubMed ID: 3606940
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetic and tumour-penetration properties of the hypoxic cell radiosensitizer desmethylmisonidazole (Ro 05-Ro-9963) in dogs.
    White RA; Workman P
    Br J Cancer; 1980 Feb; 41(2):268-76. PubMed ID: 7370166
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Radiosensitization of a mouse tumour by Ro 03-8799: acute and protracted administration.
    Hill SA; Fowler JF; Minchinton AI; Stratford MR; Denekamp J
    Int J Radiat Biol Relat Stud Phys Chem Med; 1983 Aug; 44(2):143-50. PubMed ID: 6603435
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetic studies on diponium bromide.
    Partsch G; Dunky A; Eberl R
    Int J Clin Pharmacol Res; 1983; 3(1):55-60. PubMed ID: 6679509
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dose-dependence and related studies on the pharmacokinetics of misonidazole and desmethylmisonidazole in mice.
    Workman P
    Cancer Chemother Pharmacol; 1980; 5(1):27-37. PubMed ID: 7460192
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A toxicity and pharmacokinetic study in man of the hypoxic-cell radiosensitiser RSU-1069.
    Horwich A; Holliday SB; Deacon JM; Peckham MJ
    Br J Radiol; 1986 Dec; 59(708):1238-40. PubMed ID: 3542110
    [No Abstract]   [Full Text] [Related]  

  • 30. Metabolism induced binding of 14C-misonidazole to hypoxic cells: kinetic dependence on oxygen concentration and misonidazole concentration.
    Koch CJ; Stobbe CC; Baer KA
    Int J Radiat Oncol Biol Phys; 1984 Aug; 10(8):1327-31. PubMed ID: 6469755
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A drug for improved radiosensitization in radiotherapy.
    Dische S; Fowler JF; Saunders MI; Stratford MR; Anderson P; Minchinton AI; Lee ME
    Br J Cancer; 1980 Jul; 42(1):153-5. PubMed ID: 7426325
    [No Abstract]   [Full Text] [Related]  

  • 32. A clinical phase I toxicity study of Ro 03-8799: plasma, urine, tumour and normal brain pharmacokinetics.
    Roberts JT; Bleehen NM; Walton MI; Workman P
    Br J Radiol; 1986 Feb; 59(698):107-16. PubMed ID: 3947818
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics and binding of the bioreductive probe for hypoxia, NITP: effect of route of administration.
    Hodgkiss RJ; Stratford MR; Dennis MF; Hill SA
    Br J Cancer; 1995 Dec; 72(6):1462-8. PubMed ID: 8519660
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vivo testing of a 2-nitroimidazole radiosensitizer (Ro 03-8799) using repeated administration.
    Williams MV; Denekamp J; Minchinton AI; Stratford MR
    Int J Radiat Oncol Biol Phys; 1982; 8(3-4):477-81. PubMed ID: 7107370
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The concentration of desmethylmisonidazole in human tumours and in cerebrospinal fluid.
    Dische S; Saunders MI; Riley PJ; Hauck J; Bennett MH; Stratford MR; Minchinton AI
    Br J Cancer; 1981 Mar; 43(3):344-9. PubMed ID: 7225285
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Initial report of the phase I trial of the hypoxic cell radiosensitizer SR-2508.
    Coleman CN; Urtasun RC; Wasserman TH; Hancock S; Harris JW; Halsey J; Hirst VK
    Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1749-53. PubMed ID: 6237086
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A comparison of tumor and normal tissue levels of acidic, basic and neutral 2-nitroimidazole radiosensitizers in mice.
    Minchinton AI; Stratford MR
    Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1117-20. PubMed ID: 2943710
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics of beta-methyldigoxin in healthy humans I: intravenous studies.
    Hinderling PH; Garrett ER; Wester RD
    J Pharm Sci; 1977 Feb; 66(2):242-53. PubMed ID: 839422
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics and toxicology of continuously infused nitroimidazoles.
    Eifel PJ; Brown JM
    Int J Radiat Oncol Biol Phys; 1984 Aug; 10(8):1311-4. PubMed ID: 6236186
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lack of stereoselectivity in the pharmacokinetics and metabolism of the radiosensitizer Ro 03-8799 in man.
    Workman P; Newman HF; Bleehen NM; Ward R; Smithen CE
    Cancer Chemother Pharmacol; 1991; 28(2):118-22. PubMed ID: 2060082
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.